Solventum Aktie News

ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE: SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close.

Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S. Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacency ST. PAUL, Minn.

New guidance highlights evolving surgical procedure applications of reticulated open cell foam (ROCF) dressings to support patient safety, surgical outcomes and future standards of care Solventum™  Prevena™ Therapy is the only closed incision negative pressure therapy system with fully integrated linear and area dressings solely indicated for closed incisions that utilize ROCF technology ST. PA...

ST. PAUL, Minn. , Dec. 16, 2025 /PRNewswire/ -- Solventum (NYSE: SOLV) announced today that it has achieved the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative (HIRC), the highest recognition for supply chain strength in healthcare.

Solventum offers an interesting risk/reward profile, with improving margins, disciplined reinvestment, and potential revenue growth acceleration offsetting modest core revenue growth concerns. The $725M+ Acera Surgical acquisition provides entry into a double-digit growth wound care market, though it introduces operating and sentiment risks. SOLV's 'Transform for the Future' initiative targets ...

New markets are opening up for Albemarle's lithium products. Recent 3M spinoff Solventum is finding its footing.

Solventum Corporation (SOLV) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Three stocks that are performing well in 2025 just made notable buyback announcements. All three have achieved returns north of 20% this year, beating the 18% return of the S&P 500 Index.